

Treatment of advanced prostate cancer - if, when and what?

Poster Session 04

Friday, 24 March
10:45 - 12:15

Location: Room Amsterdam, North Hall (Level 1)

Chairs: S. Bracarda, Arezzo (IT)
P. Cornford, Liverpool (GB)
A.S. Merseburger, Lübeck (DE)

Aims and objectives of this session

Data about new and established approaches for systemic treatment of prostate cancer and management of nodal disease will be presented. Differential indication of hormone ablation versus other forms of systemic treatments will be discussed together with long-term effects of androgen deprivation therapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 48 **Improved survival in patients diagnosed with metastatic prostate cancer – a nationwide analysis**
By: [Helgstrand J.T.](#)¹, Klemann N.¹, Toft B.², Vainer B.², Brasso K.¹, Brooks J.³, Iversen P.¹, Røder M.¹
Institutes:¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark, ³Stanford University Hospital, Dept. of Urology, Stanford, United States of America
- 50 **What is the optimal post-operative management of men with lymph node recurrent prostate cancer after salvage lymph node dissection? Results from a large, multi-institutional series**
By: [Briganti A.](#)¹, Fossati N.¹, Suardi N.¹, Bandini M.¹, Colicchia M.⁶, Karnes J.R.⁶, Haidl F.⁷, Pfister D.⁷, Porres D.⁷, Heidenreich A.⁷, Herlemann A.⁹, Gratzke C.⁹, Stief C.⁹, Battaglia A.⁴, Everaerts W.⁴, Joniau S.⁴, Van Poppel H.⁴, Aksenov A.V.⁸, Osmonov D.K.⁸, Jünemann K.P.⁸, Abreu A.D.L.³, Almeida F.³, Fay C.², Gill I.², Mottrie A.M.⁵, Montorsi F.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Keck School of Medicine, University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ³Phoenix Imaging Center, Dept. of Urology, Phoenix, United States of America, ⁴University Hospitals Leuven, Dept of Development and Regeneration, Leuven, Belgium, ⁵OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, ⁶Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁷University of Cologne, Dept. of Urology, Cologne, Germany, ⁸University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, ⁹Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany
- 51 **Salvage lymph node dissection in nodal recurrent prostate cancer is not devoid of complications: Results from a single tertiary referral center**
By: [Dell'Oglio P.](#)¹, Gandaglia G.¹, Stabile A.¹, Fossati N.¹, Bianchi M.², Bravi C.¹, Zaffuto E.¹, Bandini M.¹, Fallara G.¹, Gallina A.¹, Suardi N.¹, Rigatti P.³, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University, Dept. of Urology, Catanzaro, Italy, ³Advanced Urotechnology Center, Scientific Institute "Istituto Auxologico Italiano", Dept. of Urology, Milan, Italy
- 52 **Phase III study of intermittent monotherapy versus continuous combined androgen deprivation**
By: [Calais Da Silva Junior E.](#)¹, Calais Da Silva Senior F.¹, Gonçalves F.², Kliment J.³, Santos A.⁴, Pastidis S.⁵, Queimadelos A.⁶, Robertson C.⁷
Institutes:¹CHLC - Hospital de São José, Dept. of Urology, Lisbon, Portugal, ²CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, ³Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, ⁴Hospital De Braga, Dept. of Urology, Braga, Portugal, ⁵Amalia Fleming

Hospital, Dept. of Urology, Athens, Greece, ⁶Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, ⁷University of Strathclyde, Dept. of Urology, Glasgow, United Kingdom

- 53 **Chemical castration decreased the risk of dementia in patients with prostate cancer - from 13368 patients, Taiwan National Health Insurance Research Database**
 By: Hong J., Liao C., Huang C., Lu Y.
 Institutes: National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- 54 **Testosterone recovery after long time androgen deprivation therapy: The role of duration of deprivation in combination with other predictive factors**
 By: Estrada-Domínguez F.², Borque Fernando A.¹, Esteban L.³, Gil Sanz M.J.⁴, Sanz Saiz G.⁵
 Institutes: ¹Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, ²Hospital Universitario "Miguel Servet" (IIS Aragón), Dept. of Urology, Zaragoza, Spain, ³Universidad De Zaragoza, Escuela Universitaria Politécnica De La Almunia, Zaragoza, Spain, ⁴Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, ⁵Universidad De Zaragoza, Dept. of Statistical Methods, Zaragoza, Spain
- 55 **Survival following primary androgen deprivation therapy or watchful waiting among older men with localized prostate cancer**
 By: Seikkula H.¹, Boström P.², Rantanen M.³, Pitkaniemi J.³, Malila N.³, Kaipia A.⁴
 Institutes: ¹Central Hospital of Central Ostrobothnia, Dept. of Urology, Kokkola, Finland, ²Turku University Hospital, Dept. of Urology, Turku, Finland, ³Finnish Cancer Registry, Institute For Statistical and Epidemiological Cancer Research, Helsinki, Finland, ⁴Satakunta Hospital District, Dept. of Urology, Pori, Finland
- 56 **Does prostate cancer represent the main cause of death in all node positive prostate cancer patients? The impact of competing causes of mortality according to tumor characteristics and recurrence status**
 By: Dell'Oglio P.¹, Zaffuto E.¹, Stabile A.¹, Gandaglia G.¹, Colicchia M.², Fossati N.¹, Capitanio U.¹, Dehò F.¹, Colombo R.¹, Bertini R.¹, Montorsi F.¹, Karnes J.², Briganti A.¹
 Institutes: ¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America
- 57 **Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)**
 By: Saad F.¹, Heinrich D.², Gillissen S.³, O'Sullivan J.⁴, Carles J.⁵, Wirth M.⁶, Miller K.⁷, Huang L.⁸, Seger M.⁹, Nilsson S.¹⁰, Heidenreich A.¹¹
 Institutes: ¹University of Montreal Hospital Center, Dept. of GU Oncology, Montréal, Canada, ²Akershus University Hospital, Dept. of Oncology, Lørenskog, Norway, ³Kantonsspital St Gallen, Dept. of Oncology, St Gallen, Switzerland, ⁴The Northern Ireland Cancer Centre, Dept. of Radiation Oncology, Belfast, United Kingdom, ⁵Vall D' Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ⁶University Hospital Carl-Gustav Carus, Dept. of Urology, Dresden, Germany, ⁷Charité University Medicine Berlin, Dept. of Urology, Berlin, Germany, ⁸Pharmaceutical Division of Bayer, Dept. of Statistics, Whippany, United States of America, ⁹Pharmaceutical Division of Bayer, Dept. of Global Medical Affairs, Whippany, United States of America, ¹⁰Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden, ¹¹University Hospital Cologne, Dept. of Urology, Cologne, Germany
- 58 **The importance of imaging studies to monitor treatment with novel AR-targeted agents in metastatic castration resistant prostate cancer (mCRPC)**
 By: Heidegger L., Kohl T., Pfister D., Friederike H., Paffenholz P., Heidenreich A.
 Institutes: Uniklinik Köln, Dept. of Urology, Cologne, Germany
- 59 **Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial**
 By: Nabid A.¹, Garant M-P.², Martin A-G.³, Souhami L.⁴, Duclos M.⁴, Bahary J-P.⁵, Lemaire C.⁶, Vass S.⁷, Archambault R.⁸, Vincent F.⁹, Bahoric B.¹¹, Bettahar R.¹⁰

Institutes:¹Centre Hospitalier Universitaire de Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, ²Centre Hospitalier Universitaire de Sherbrooke, Biostatistical Services, Sherbrooke, Canada, ³Centre Hospitalier Universitaire de Québec, Dept. of Radio-Oncology, Québec, Canada, ⁴Centre Universitaire de Santé McGill, Dept. of Radio-Oncology, Montréal, Canada, ⁵Centre Hospitalier Universitaire de Montréal, Dept. of Radio-Oncology, Montréal, Canada, ⁶Hôpital Maissonneuve-Rosemont, Dept. of Radio-Oncology, Montréal, Canada, ⁷Centre de Santé et Services Sociaux de Chicoutimi, Dept. of Radio-Oncology, Chicoutimi, Canada, ⁸Hôpital De Gatineau, Dept. of Radio-Oncology, Gatineau, Canada, ⁹Centre Hospitalier Régional de Trois-Rivières, Dept. of Radio-Oncology, Trois-Rivières, Canada, ¹⁰Centre Hospitalier Régional de Rimouski, Dept. of Radio-Oncology, Rimouski, Canada, ¹¹Hôpital Général Juif de Montréal, Dept. of Radio-Oncology, Montréal, Canada

60

Semi-ecologic, nationwide, population-based study of GnRH agonists, orchiectomy and risk of cardiovascular disease

By: [Stattin P.](#)¹, Thomsen F.B.², Sandin F.³, Garmo H.⁴, Ahlgren G.⁵, Lissbrant I.F.⁶, Van Hemelrijck M.⁴, Adolfsson J.⁷, Robinson D.⁸

Institutes:¹Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden, ²Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ³Uppsala University Hospital, Regional Cancer Centre Uppsala Örebro, Uppsala, Sweden, ⁴King's College London, School of Medicine, Dept. of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom, ⁵SUS Malmö, Dept. of Urology, Malmö, Sweden, ⁶University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, ⁷Karolinska Institutet, CLINTEC-Dept, Stockholm, Sweden, ⁸Umeå University Hospital, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden

12:00 - 12:10

Advanced prostate cancer - A wide range of treatment options and challenges

A.S. Merseburger, Lübeck (DE)